Daniel Harnsberger, MD
Obstetrics & Gynecology · Chattanooga, TNNPI 1922073808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $824 and has fallen 50.6% since, to $408 in 2025.
Across 154 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$376
- AbbVie$282
- Myovant Sciences Inc.$264
- Sage Therapeutics, LLC$260
- Sumitomo Pharma America, Inc.$256
- Daiichi Sankyo Inc.$140
- plus $1K from 30 others
Across 562 payments — averaging $4427.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$986K
- Sumitomo Pharma America, Inc.$493K
- Exeltis, USA Inc.$355K
- Roche Molecular Systems, Inc.$223K
- Abbott$101K
- Mylan Inc.$80K
- plus $249K from 7 others
What the payments were for
- Food & beverage$2,80796%
- Education$1234%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $376 |
| AbbVie(2 entities) | 16 | $282 |
| Myovant Sciences Inc. | 18 | $264 |
| Sage Therapeutics, LLC | 14 | $260 |
| Sumitomo Pharma America, Inc. | 13 | $256 |
| Daiichi Sankyo Inc. | 8 | $140 |
| Pfizer | 7 | $126 |
| Bayer | 6 | $118 |
| Shield Therapeutics Inc | 3 | $97 |
| Exeltis, USA Inc. | 6 | $84 |
| Aspira Women's Health Inc | 2 | $81 |
| Novo Nordisk | 3 | $73 |
| Organon | 4 | $72 |
| Merck | 5 | $69 |
| Millicent US Inc | 3 | $64 |
| Therapeuticsmd, Inc. | 4 | $63 |
| Mayne Pharma Commercial LLC | 3 | $62 |
| Avion Pharmaceuticals | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Baxter Healthcare | 2 | $40 |
| Channel Medsystems, Inc. | 1 | $38 |
| Roche Diagnostics Corporation | 2 | $37 |
| Smith+Nephew | 2 | $28 |
| Currax Pharmaceuticals LLC | 2 | $23 |
| AMAG Pharmaceuticals, Inc. | 2 | $23 |
| Gynesonics, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Intuitive Surgical | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Amgen | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
How this compares
$2,929 in reported general payments places this provider in the 75th percentile of 763 obstetrics & gynecology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 19 | $7,072 |
| Estradiol | 80 | $1,873 |
| ProgesteroneProgesterone, Micronized | 13 | $357 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $126 | $7,07219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 763 obstetrics & gynecology providers in Tennessee.
Other obstetrics & gynecology in Chattanooga
- Rayan ElkattahChattanooga$26K
- Kent ChildsChattanooga$23K
- Linda YuChattanooga$19K
- Gary BrunvollChattanooga$11K
- Shevonda SherrowChattanooga$9K
- Jack RowlandChattanooga$7K
- Grover MayJohnson City$916K
- John GreenElizabethton$878K
- Brent LaingElizabethton$480K
- Larry FieldsKnoxville$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.